Jury Invalidates PacBio's Patents in U.S. Patent Trial Against Oxford Nanopore
OXFORD, England, March 18, 2020 /CNW/ -- After more than one week of evidence, a federal jury in Delaware found in favour of Oxford Nanopore and invalidated all four patents asserted by Pacific Biosciences ("PacBio") in this litigation.
This outcome follows positive outcomes for Oxford Nanopore in previous proceedings.
Dr Gordon Sanghera, CEO of Oxford Nanopore, said: "We are pleased that the jury recognized that it is Oxford Nanopore, with the help of our collaborators across the globe and as part of the thriving nanopore community of users, who are the true innovators in the field of nanopore sequencing."
Dr. Sanghera added: "We will continue to deliver innovative sequencing technology to our customers, who are using the technology to make a profound, positive impact on society. "
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed,...
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
